HY-100013A1-10mg
|
MedChemexpress LLC
|
(1R,2R)-2-PCCA (hydrochloride) [CAS 1609563-71-4]
|
|
Neuroscience-Neuromodulation
|
|
HY-100013A1-25mg
|
MedChemexpress LLC
|
(1R,2R)-2-PCCA (hydrochloride) [CAS 1609563-71-4]
|
|
Neuroscience-Neuromodulation
|
|
HY-100013A1-5mg
|
MedChemexpress LLC
|
(1R,2R)-2-PCCA (hydrochloride) [CAS 1609563-71-4]
|
|
Neuroscience-Neuromodulation
|
|
HY-100013A1-50mg
|
MedChemexpress LLC
|
(1R,2R)-2-PCCA (hydrochloride) [CAS 1609563-71-4]
|
|
Neuroscience-Neuromodulation
|
|
HY-10126-10mg
|
MedChemexpress LLC
|
Barasertib-HQPA [CAS 722544-51-6]
|
|
Cancer-Kinase/protease
|
|
HY-10126-100mg
|
MedChemexpress LLC
|
Barasertib-HQPA [CAS 722544-51-6]
|
|
Cancer-Kinase/protease
|
|
HY-10126-5mg
|
MedChemexpress LLC
|
Barasertib-HQPA [CAS 722544-51-6]
|
|
Cancer-Kinase/protease
|
|
HY-10126-50mg
|
MedChemexpress LLC
|
Barasertib-HQPA [CAS 722544-51-6]
|
|
Cancer-Kinase/protease
|
|
HY-10127-10mg
|
MedChemexpress LLC
|
Barasertib [CAS 722543-31-9]
|
|
Cancer-Kinase/protease
|
|
HY-10127-5mg
|
MedChemexpress LLC
|
Barasertib [CAS 722543-31-9]
|
|
Cancer-Kinase/protease
|
|
HY-10127-50mg
|
MedChemexpress LLC
|
Barasertib [CAS 722543-31-9]
|
|
Cancer-Kinase/protease
|
|
HY-114400-1mg
|
MedChemexpress LLC
|
TRPV4 agonist-1 (free base) [CAS 2314467-59-7]
|
|
COVID-19-immunoregulation
|
|
HY-114400-10mg
|
MedChemexpress LLC
|
TRPV4 agonist-1 (free base) [CAS 2314467-59-7]
|
|
COVID-19-immunoregulation
|
|
HY-114400-100mg
|
MedChemexpress LLC
|
TRPV4 agonist-1 (free base) [CAS 2314467-59-7]
|
|
COVID-19-immunoregulation
|
|
HY-114400-25mg
|
MedChemexpress LLC
|
TRPV4 agonist-1 (free base) [CAS 2314467-59-7]
|
|
COVID-19-immunoregulation
|
|
HY-114400-5mg
|
MedChemexpress LLC
|
TRPV4 agonist-1 (free base) [CAS 2314467-59-7]
|
|
COVID-19-immunoregulation
|
|
HY-114400-50mg
|
MedChemexpress LLC
|
TRPV4 agonist-1 (free base) [CAS 2314467-59-7]
|
|
COVID-19-immunoregulation
|
|
HY-114778-10mg
|
MedChemexpress LLC
|
Fluzoparib [CAS 1358715-18-0]
|
|
Cancer-programmed cell death
|
|
HY-114778-100mg
|
MedChemexpress LLC
|
Fluzoparib [CAS 1358715-18-0]
|
|
Cancer-programmed cell death
|
|
HY-114778-25mg
|
MedChemexpress LLC
|
Fluzoparib [CAS 1358715-18-0]
|
|
Cancer-programmed cell death
|
|
HY-114778-5mg
|
MedChemexpress LLC
|
Fluzoparib [CAS 1358715-18-0]
|
|
Cancer-programmed cell death
|
|
HY-114778-50mg
|
MedChemexpress LLC
|
Fluzoparib [CAS 1358715-18-0]
|
|
Cancer-programmed cell death
|
|
HY-115510-10mg
|
MedChemexpress LLC
|
SPR inhibitor 3 [CAS 1292285-54-1]
|
|
COVID-19-immunoregulation
|
|
HY-115510-100mg
|
MedChemexpress LLC
|
SPR inhibitor 3 [CAS 1292285-54-1]
|
|
COVID-19-immunoregulation
|
|
HY-115510-5mg
|
MedChemexpress LLC
|
SPR inhibitor 3 [CAS 1292285-54-1]
|
|
COVID-19-immunoregulation
|
|